🇺🇸 thyrotropin-releasing hormone in United States
6 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 6
Most-reported reactions
- Drug Ineffective — 1 report (16.67%)
- Illness — 1 report (16.67%)
- Obstructive Airways Disorder — 1 report (16.67%)
- Salivary Hypersecretion — 1 report (16.67%)
- Status Epilepticus — 1 report (16.67%)
- Toxicity To Various Agents — 1 report (16.67%)
Other Endocrinology approved in United States
Frequently asked questions
Is thyrotropin-releasing hormone approved in United States?
thyrotropin-releasing hormone does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for thyrotropin-releasing hormone in United States?
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is the originator. The local marketing authorisation holder may differ — check the official source linked above.